Research delivers insight into the Osteoarthritis - Pipeline Review, H1 2017
Osteoarthritis - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Osteoarthritis (Immunology) pipeline landscape.
Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.
Complete report available @ Osteoarthritis - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.
Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Abiogen Pharma SpA Ablynx NV Achelios Therapeutics Inc Addex Therapeutics Ltd Amgen Inc Amura Holdings Ltd Arcarios BV Asahi Kasei Pharma Corp Asklepios BioPharmaceutical Inc Astellas Pharma Inc Biopharm GmbH Bone Therapeutics SA Can-Fite BioPharma Ltd Cardax Inc Cellular Biomedicine Group Inc Cipla Ltd Corestem Inc Dong-A Socio Holdings Co Ltd Evgen Pharma Plc F. Hoffmann-La Roche Ltd Galapagos NV Gemphire Therapeutics Inc GeneFrontier Corp Genequine Biotherapeutics GmbH GlaxoSmithKline Plc HSRx Group InKemia IUCT Group SA International Stem Cell Corp Jeil Pharmaceutical Co Ltd Jenrin Discovery Inc K-Stemcell Co Ltd Kang Stem Biotech Co Ltd Levolta Pharmaceuticals Inc LG Chem, Ltd. Marina Biotech Inc Medivir AB Merck KGaA Mesoblast Ltd Mor Research Application Ltd NicOx SA Nordic Bioscience A/S Novartis AG NovelMed Therapeutics Inc Omeros Corp Ono Pharmaceutical Co Ltd OrthoCyte Corp Osteologix Holdings Plc Pfizer Inc Pharmalink AB Philogen SpA PhytoHealth Corp PLx Pharma Inc ProteoThera Inc Regeneus Ltd Regulaxis SAS Rottapharm Biotech Srl Samumed LLC Seikagaku Corp Stelis Biopharma Pvt Ltd Takeda Pharmaceutical Company Ltd TissueGene Inc Yooyoung Pharmaceutical Co Ltd Yuhan Corp Yungjin Pharm Co Ltd Zimmer Biomet Holdings Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 03:08
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home